Navigation Links
Cardiome meldet Veröffentlichung positiver Ergebnisse aus Vergleichsstudie von Vernakalant IV mit Propafenon und Flecainid
Date:9/24/2013

? Journal of Atrial Fibrillation. 2013;6(2). Online-Zugriff am 17. September 2013

Informationen zur Cardiome Pharma Corp.

Die Cardiome Pharma Corp. ist ein Biopharmaunternehmen, das sich der Entdeckung, Entwicklung und Vermarktung von neuen Therapien verschrieben hat, die der Gesundheit von Patienten aus aller Welt zugutekommen. Das einzige von Cardiome vermarktete Produkt BRINAVESS[TM] (Vernakalant IV) ist in Europa und anderen Gebieten zur raschen Konversion von jüngst ausgebrochenem Vorhofflimmern zum Sinusrhythmus bei Erwachsenen zugelassen.

Die Aktien von Cardiome sind am NASDAQ Capital Market (CRME) und an der Börse Toronto (COM) gelistet. Nähere Informationen erhalten Sie auf unserer Website http://www.cardiome.com.

Haftungsausschluss in Bezug auf vorausschauende Aussagen

Bestimmte Aussagen in dieser Pressemitteilung enthalten vorausschauende Aussagen im Sinne des Private Securities Litigation Reform Act von 1995 bzw. zukunftsgerichtete Informationen im Sinne gültiger kanadischer Wertpapiergesetze, die unter Umständen nicht auf historischen Tatsachen beruhen. Ohne jegliche Einschränkung zählen hierzu Aussagen, die die Begriffe "glauben", "können", "planen", "werden", "schätzen", "weiterhin", "antizipieren", "beabsichtigen, "erwarten" sowie ähnliche Formulierungen enthalten. Vorausschauende Aussagen können unter Umständen Bemerkungen bezüglich unserer Ziele und Prioritäten für den verbleibenden Teil des Jahres 2013 und darüber hinaus enthalten, sind aber nicht auf solche beschränkt. Zudem können sie sich auf Strategien und zukünftige Maßnahmen, Zielvorgaben, Erwartungen bezüglich unserer finanziellen Lage sowie auf die Ergebnisse und Prognosen unserer Geschäfts-, Forschungs- und Entwicklungsaktivitäten und unserer
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cardiometabolic Health Congress Expert Faculty Evaluate the Clinical Implications of Newly FDA-Approved Treatment for Homozygous Familial Hypercholesterolemia
2. Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... May 26, 2015 Innovacyn, a ... in the human and animal health industries, announced ... Future Innovators of Agriculture College Scholarship Award. The ... who exhibits a passionate commitment to the agriculture ... This year’s winners, Alexis Pedrow from Anderson County ...
(Date:5/26/2015)... 2015  Sangamo BioSciences, Inc. (NASDAQ: SGMO ) announced ... will provide an update on the progress of Sangamo,s ZFP ... company,s business strategy at 1:30pm ET on Monday, June 1, ... is being held in New York, NY ... may be accessed via a link on the Sangamo BioSciences ...
(Date:5/26/2015)... China , May 26, 2015 Tianyin ... company that specializes in the patented biopharmaceutical, modernized traditional ... (API), announced that the Company,s Annual Meeting of Shareholders ... scheduled to be held at the Company,s office located ... conference call, at 9:00 AM (local time in ...
(Date:5/26/2015)... , May 26, 2015   PDI ... solutions, today announced that Oakwood Healthcare in ... as the winning entry in Delivering ... professionals who display excellence in building collaborative relationships ... teams in healthcare facilities.  Oakwood ...
Breaking Biology Technology:Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 2Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 3Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 3PDI Announces Winner in Delivering the Difference Contest 2PDI Announces Winner in Delivering the Difference Contest 3
... Dec. 20 CuraGen Corporation,(Nasdaq: CRGN ), ... the appointment of Sean Cassidy, as Vice,President and ... announced today that David M. Wurzer will step ... pursue other opportunities, but will remain,with the Company ...
... Human Genome,Sciences, Inc. (Nasdaq: HGSI ) ... in a Phase 2 clinical trial of HGS-ETR1 ... carboplatin as,first-line therapy in patients with advanced non-small ... who are newly diagnosed with non-small cell,lung cancer ...
... Northwest,Biotherapeutics, Inc. (OTC Bulletin Board: NWBO; ... today that Lonza Group AG has,withdrawn all ... and other NWBT DCVax(R) products other than ... vaccine products infringed,certain gene expression technology patents ...
Cached Biology Technology:CuraGen Corporation Announces Appointment of Sean Cassidy as CFO 2CuraGen Corporation Announces Appointment of Sean Cassidy as CFO 3CuraGen Corporation Announces Appointment of Sean Cassidy as CFO 4Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 2Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 3Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 4Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 5Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 6Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics 2Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics 3Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics 4
(Date:5/21/2015)... 2015 The Sync Project™ , a ... health, today announced a collaborative partnership with Berklee,s ... center on collaboration on original research, joint course development ... the collaboration, The Sync Project and BerkleeICE are exploring ... in the 2015-2016 academic year.  The ...
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
(Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS delegation ... had a strong showing at AUVSI,s Unmanned 2015 conference ... of Ohio,s UAS industry met with ... from all points along the UAS ecosystem. ... (DDC) Vice President for Aerospace Rich Knoll . "If ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Genetic Testing Market Outlook 2018 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... called ,pestilences, three are historically recognized as due to ... 19th to 21st centuries AD there were microbiological evidences ... pestis . "For a long time scholars from different ... of the past pandemics. Only ancient DNA analyses carried ...
... , May 9, 2013 Wexford Science & ... in the Wake Forest Innovation Quarter , today ... buildings currently underway represents an additional $150 million investment ... Wexford,s total investment in the Innovation Quarter to more ...
... NY and San Diego, CA A large, multi-institutional research ... a sweeping analysis in the current issue of the journal ... off to direct early human development. Led by Bing Ren ... The Salk Institute for Biological Studies and James Thomson of ...
Cached Biology News:Scientists confirm that the Justinianic Plague was caused by the bacterium Yersinia pestis 2Wexford Science & Technology Makes $150 Million Investment in Wake Forest Innovation Quarter 2Wexford Science & Technology Makes $150 Million Investment in Wake Forest Innovation Quarter 3Mapping the embryonic epigenome 2Mapping the embryonic epigenome 3
Request Info...
... Provides a buffered anti-freeze environment for enzyme ... a liquid, low viscosity solution at -20C ... necessary and sampling is convenient , ... long-term storage Protect enzyme conjugates during ...
Request Info...
... system, which is based on a new flow-through ... performing in situ hybridization of tissues on microscope ... the study of gene expression, in situ hybridization ... and can be used to validate and confirm ...
Biology Products: